Carmen Serrano-Munuera

Carmen Serrano-Munuera

Auto-generated profile, based on publicly available information

Carmen Serrano-Munuera

Departamento de Medicina. Fundació Hospital Sant Joan de Déu de Martorell. Facultad de Medicina. FESS. UVIC-UCC. IRIS-CC

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1998 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JLJing Liu
Jing Liu
MAMasashi Aoki
Masashi Aoki
IIIsabel Illa
Isabel Illa
CWChenyan Wu
Chenyan Wu
MFMichel Fardeau
Michel Fardeau
RBRobert H. Brown
Robert H. Brown

25 May 2010 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
VMVinod Malik
Vinod Malik
LRLouise R. Rodino‐Klapac
Louise R. Rodino‐Klapac
LVLaurence Viollet
Laurence Viollet
CWCheryl Wall
Cheryl Wall
WKWendy King
Wendy King
JMJerry R. Mendell
Jerry R. Mendell

1 October 2006 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Open access
PDF file
SMSteven A Moore
Steven A Moore
CSChristopher J. Shilling
Christopher J. Shilling
SWSteven Westra
Steven Westra
CWCheryl Wall
Cheryl Wall
MWMatthew P. Wicklund
Matthew P. Wicklund
JMJerry R. Mendell
Jerry R. Mendell
Limb-girdle muscular dystrophy (LGMD) has been linked to 15 chromosomal loci, 7 autosomal-dominant (LGMD1A to E) and 10 autosomal-recessive (LGMD2A t

1 December 1998 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
JMJose Luis Molinuevo
Jose Luis Molinuevo
Francesc GrausFrancesc Graus
Francesc Graus
CSCarmen Serrano
Carmen Serrano
RRRamón Reñe
Ramón Reñe
AGAntonio Guerrero
Antonio Guerrero
IIIsabel Illa
Isabel Illa

1 October 2011 in The Cerebellum
Verified
Journal Article
Closed access
PDF file
OGOn behalf of the Iberoamerican Multidisciplinary Network for the Study of Movement Disorders (RIBERMOV) Study Group
On behalf of the Iberoamerican Multidisciplinary Network for the Study of Movement Disorders (RIBERMOV) Study Group
JSJonas Alex Morales Saute
Jonas Alex Morales Saute
KDKarina Carvalho Donis
Karina Carvalho Donis
CSCarmen Serrano-Munuera
Carmen Serrano-Munuera
DGDavid Genis
David Genis
LJLaura Bannach Jardim
Laura Bannach Jardim

28 August 2001 in Neurology
Verified
Journal Article
Closed access
PDF file
JMJ. R. Mendell
J. R. Mendell
CBC. H. Buzin
C. H. Buzin
JFJ. Feng
J. Feng
JYJ. Yan
J. Yan
CSC. Serrano
C. Serrano
SSS. S. Sommer
S. S. Sommer
Objective: To determine whether detection of small mutations of the dystrophin gene can be increased using an enhanced method of single-strand conformation polymorphism analysis. Background: Usual methods of DNA analysis for Duchenne dystrophy cannot identify mutations in one-third of cases. Muscle biopsy, with its inherent risks and added liability for patients with Duchenne dystrophy, becomes the sole method of diagnosis. Even with a tissue diagnosis of dystrophin deficiency, many families are excluded from carrier detection and prenatal diagnosis. Methods: Genomic DNA from a cohort of 93 patients with Duchenne dystrophy without identifiable gene mutations was screened for mutations. In each case, 22 kilobases of genomic DNA were scanned, including all 79 exons of the dystrophin gene, adjacent intronic regions, and six alternative exons 1. Results: Sixty-eight (73%) had small mutations, including 34 nonsense mutations, 27 microdeletions and insertions, and 7 splice site mutations. No missense mutations were found. One nonsense mutation in exon 59 was detected in four patients. Most mutations were new; 54 of 62 different small mutations have not been reported. Mutations were found throughout the gene: 24% in the first quartile, 31% in the second, 16% in the third, and 29% in the fourth. Conclusions: A highly sensitive single-strand conformation polymorphism method substantially increased detection of small dystrophin gene mutations and made it possible to diagnose approximately 90% of patients with Duchenne dystrophy by DNA analysis. These findings, combined with cost savings and safety issues, provide compelling reasons to consider DNA analysis as the initial diagnostic test for the suspected dystrophin-deficient patient.